ModernGraham Valuation

Company Name:

Amgen, Inc.

Company Ticker

AMGN

Date of Analysis 8/25/2016



Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

Defensive Investor; must pass 6 out of the following 7 tests.

 Adequate Size of the Enterprise 	Market Cap > \$2Bil	\$125,357,511,402 Pass
2. Sufficiently Strong Financial Condition	Current Ratio > 2	3.97 Pass
3. Earnings Stability	Positive EPS for 10 years prior	Pass
4. Dividend Record	Dividend Payments for 10 years prior	Fail
	Increase of 33% in EPS in past 10 years using 3 year averages at	
5. Earnings Growth	beginning and end	133.78% Pass
6. Moderate PEmg Ratio	PEmg < 20	20.34 Fail
7. Moderate Price to Assets	PB Ratio < 2.5 OR PB*PEmg < 50	4.29 Fail

Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.

1. Sufficiently Strong Financial Condition	Current Ratio > 1.5	3.97 Pass
2. Sufficiently Strong Financial Condition	Debt to NCA < 1.1	0.87 Pass
3. Earnings Stability	Positive EPS for 5 years prior	Pass
4. Dividend Record	Currently Pays Dividend	Pass
5. Earnings Growth	EPSmg greater than 5 years ago	Pass

Suitability

MG Opinion

Defensive No Enterprising Yes

Stage 2: Determination of Intrinsic Value

EPSmg	\$8.41
MG Growth Estimate	11.67%
MG Value	\$267.63
MG Value based on 3% Growth	\$121.89
MG Value based on 0% Growth	\$71.45
Market Implied Growth Rate	5.92%
Current Price	\$171.00
% of Intrinsic Value	63.90%
Opinion	Undervalued

В

Stage 3: Information for Further Research

MG Grade

Net Current Asset Value (NCAV)	-\$3.16
Graham Number	\$96.05
PEmg	20.34
Current Ratio	3.97
PB Ratio	4.29
Current Dividend	\$3.58
Dividend Yield	2.09%
Number of Consecutive Years of Dividend Growth	6

Useful Links:


ModernGraham tagged articles

Google Finance
Yahoo Finance
GuruFocus

Morningstar
MSN Money
Seeking Alpha
SEC Filings

EPS History		EPSmg History	
Next Fiscal Year Estimate	\$10.19	Next Fiscal Year Estimate	\$8.41
Dec2015	\$9.06	Dec2015	\$7.14
Dec2014	\$6.70	Dec2014	\$5.97
Dec2013	\$6.64	Dec2013	\$5.43
Dec2012	\$5.52	Dec2012	\$4.73
Dec2011	\$4.04	Dec2011	\$4.22
Dec2010	\$4.79	Dec2010	\$4.09
Dec2009	\$4.51	Dec2009	\$3.60
Dec2008	\$3.77	Dec2008	\$3.02
Dec2007	\$2.82	Dec2007	\$2.54
Dec2006	\$2.48	Dec2006	\$2.1
Dec2005	\$2.93	Dec2005	\$1.70
Dec2004	\$1.81	Dec2004	\$1.02
Dec2003	\$1.69	Dec2003	\$0.6
Dec2002	-\$1.21	Dec2002	\$0.2
Dec2001	\$1.03	Dec2001	\$0.98
Dec2000	\$1.05	Dec2000	\$0.90
Dec1999	\$1.02	Balance Sheet Information	6/1/2016
Dec1998	\$0.82	Total Current Assets	\$42,947,000,000
Dec1997	\$0.59	Total Current Liabilities	\$10,830,000,000
Dec1996	\$0.61	Long-Term Debt	\$27,928,000,000
		Total Assets	\$75,471,000,000
		Intangible Assets	\$25,867,000,000
		Total Liabilities	\$45,338,000,000
		Shares Outstanding (Diluted Average)	756,000,000





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor.

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

Other ModernGraham posts about the company Amgen Inc Valuation – February 2016 \$AMGN

5 Undervalued Companies with a Low Beta – October 2015

10 Best Stocks For Value Investors This Week – 9/26/15

Amgen Inc. Analysis – September 2015 Update \$AMGN

Amgen Inc Valuation – February 2016 \$AMGN

Other ModernGraham posts about related companies Pfizer Inc Valuation – August 2016 \$PFE

Abbott Laboratories Valuation – August 2016 \$ABT

Johnson & Johnson Valuation – August 2016 \$JNJ

Regeneron Pharmaceuticals Inc Valuation – August 2016 \$REGN

AmerisourceBergen Corp Valuation – July 2016 \$ABC

Perrigo Co PLC Valuation - July 2016 \$PRGO

AbbVie Inc Valuation - July 2016 \$ABBV

Gilead Sciences Inc Valuation - July 2016 \$GILD

Eli Lilly and Company Valuation - July 2016 \$LLY

Zoetis Inc Valuation – June 2016 \$ZTS